BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimokawa M, Yoshizumi T, Itoh S, Iseda N, Sakata K, Yugawa K, Toshima T, Harada N, Ikegami T, Mori M. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma. Cancer Sci 2020;111:1228-40. [PMID: 31968140 DOI: 10.1111/cas.14320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Sousa B, Pereira J, Marques R, Grilo LF, Pereira SP, Sardão VA, Schmitt F, Oliveira PJ, Paredes J. P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress. Biochim Biophys Acta Mol Basis Dis 2020;1866:165964. [PMID: 32920119 DOI: 10.1016/j.bbadis.2020.165964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Yugawa K, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Kitamura Y, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatol Commun 2021. [PMID: 34687175 DOI: 10.1002/hep4.1838] [Reference Citation Analysis]
3 Shah MA, Rogoff HA. Implications of reactive oxygen species on cancer formation and its treatment. Semin Oncol 2021;48:238-45. [PMID: 34548190 DOI: 10.1053/j.seminoncol.2021.05.002] [Reference Citation Analysis]
4 Iseda N, Itoh S, Yoshizumi T, Yugawa K, Morinaga A, Tomiyama T, Toshima T, Kohashi K, Oda Y, Mori M. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma. Hepatol Commun 2021;5:675-88. [PMID: 33860125 DOI: 10.1002/hep4.1659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatol Commun 2021;5:334-48. [PMID: 33553979 DOI: 10.1002/hep4.1643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Orrù C, Giordano S, Columbano A. Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases. Cancers (Basel) 2020;12:E2932. [PMID: 33053665 DOI: 10.3390/cancers12102932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Shimokawa M, Yoshizumi T, Itoh S, Iseda N, Sakata K, Yugawa K, Toshima T, Harada N, Ikegami T, Mori M. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma. Cancer Sci 2020;111:1228-40. [PMID: 31968140 DOI: 10.1111/cas.14320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
8 Jaganjac M, Milkovic L, Sunjic SB, Zarkovic N. The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies. Antioxidants (Basel) 2020;9:E1151. [PMID: 33228209 DOI: 10.3390/antiox9111151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]